Please ensure Javascript is enabled for purposes of website accessibility

Why RedHill Biopharma Is Trouncing the Market Today

By Eric Volkman - Apr 27, 2020 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's opaganib shows promise in the fight against the SARS-CoV-2 coronavirus following the completion of a compassionate-use program.

What happened

RedHill Biopharma (RDHL -4.67%) shot as much as 16% higher on Monday morning following the very encouraging news that one of its pipeline drugs showed promise in the treatment of patients infected with the SARS-CoV-2 coronavirus.

Close up of coronavirus.

Image source: Getty Images.

So what

That drug, opaganib, was administered in a 14-day compassionate-use program in Israel to a group of six hospitalized patients suffering from moderate to severe acute respiratory symptoms arising from the coronavirus.

RedHill said preliminary data indicates that the six "demonstrated objective significant measurable clinical improvement within days following treatment initiation."

Opaganib is an oral medication that targets several oncological, gastrointestinal, and inflammatory indications. Compassionate use is when an extremely ill patient is allowed to be administered a drug that has not yet received regulatory approval if there are no other suitable treatments available.

Now what

The world is holding its collective breath for a medication that will treat the coronavirus and/or the disease it causes, COVID-19. So any news of possible efficacious treatment will send the relevant stock skyward purely on hope.

There is much investigational work to be done on opaganib; this compassionate-use program was very small. RedHill has submitted an Investigational New Drug Application (NDA) to the FDA for a randomized clinical study of COVID-19 patients in the U.S. It says that studies are also being planned in Israel and Italy. Many eyes will be on the company to see how opaganib fares when put through those paces.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

RedHill Biopharma Ltd. Stock Quote
RedHill Biopharma Ltd.
$1.02 (-4.67%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.